BioSpace News Archive

CSL Seqirus commends the National Advisory Committee on Immunization’s recent recommendation for adults 65 years of age and older to preferentially receive an enhanced influenza vaccine, which includes adjuvanted, high-dose and recombinant vaccines.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer, effective 31 January 2024.

Sosei Group Corporation, announces its President & CEO, Chris Cargill, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has entered into a grant agreement with The Michael J. Fox Foundation for Parkinson’s Research and has been awarded funding amounting to over USD 2 million.

HOOKIPA Pharma Inc. announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, reported new data from the 12-month long-term open label extension of the CNM-Au8® treatment arm in the HEALEY ALS Platform Trial.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST.

Pluri Inc. announced it has signed an agreement assigning the joint patent rights to develop Pluri’s PLX cells in the treatment of cocaine addiction, to BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University.

Carisma Therapeutics Inc. today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd., is gearing up for participation in the JP Morgan 42nd Annual Healthcare Week, scheduled to run from January 8 to 11, 2024, in San Francisco.